company background image
ALTS logo

ALT5 Sigma NasdaqCM:ALTS Stock Report

Last Price

US$3.84

Market Cap

US$54.0m

7D

-2.0%

1Y

514.4%

Updated

22 Dec, 2024

Data

Company Financials

ALT5 Sigma Corporation

NasdaqCM:ALTS Stock Report

Market Cap: US$54.0m

My Notes

Capture your thoughts, links and company narrative

ALT5 Sigma Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for ALT5 Sigma
Historical stock prices
Current Share PriceUS$3.84
52 Week HighUS$5.26
52 Week LowUS$0.50
Beta2.1
1 Month Change75.34%
3 Month Change98.96%
1 Year Change514.40%
3 Year Change-12.73%
5 Year Change31.06%
Change since IPO-97.92%

Recent News & Updates

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

Nov 15
Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

Recent updates

Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

Nov 15
Does ALT5 Sigma (NASDAQ:ALTS) Have A Healthy Balance Sheet?

JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

Mar 31
JanOne Inc.'s (NASDAQ:JAN) Share Price Boosted 153% But Its Business Prospects Need A Lift Too

JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Feb 14
JanOne Inc. (NASDAQ:JAN) Stock Catapults 75% Though Its Price And Business Still Lag The Industry

Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

Oct 03
Shareholders May Be A Bit More Conservative With JanOne Inc.'s (NASDAQ:JAN) CEO Compensation For Now

JanOne to acquire Soin Therapeutics

Sep 16

Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?

Aug 17
Does JanOne (NASDAQ:JAN) Have A Healthy Balance Sheet?

Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?

Mar 21
Health Check: How Prudently Does JanOne (NASDAQ:JAN) Use Debt?

Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?

Nov 19
Is JanOne (NASDAQ:JAN) Using Debt In A Risky Way?

JanOne adds Nicholas Goeders to scientific advisory board

Jun 15

JanOne advances toward initiation of mid-stage peripheral artery disease trial

Jun 08

JanOne under pressure on pricing $6M stock offering

Jan 29

Shareholder Returns

ALTSUS PharmaceuticalsUS Market
7D-2.0%-1.5%-2.4%
1Y514.4%7.9%23.4%

Return vs Industry: ALTS exceeded the US Pharmaceuticals industry which returned 7.9% over the past year.

Return vs Market: ALTS exceeded the US Market which returned 23.4% over the past year.

Price Volatility

Is ALTS's price volatile compared to industry and market?
ALTS volatility
ALTS Average Weekly Movement13.3%
Pharmaceuticals Industry Average Movement10.5%
Market Average Movement6.3%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: ALTS's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ALTS's weekly volatility has decreased from 20% to 13% over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
19765Peter Tassiopoulosalt5sigma.com

ALT5 Sigma Corporation operates a next generation blockchain platform. It engages in the tokenization, trading, clearing settlement, payment, and safe keeping of digital assets. The company’s products include ALT 5 Prime, an electronic over-the-counter trading platform to buy and sell digital assets; and ALT 5 Pay that enables payment processors to accept digital assets as payments, as well as make payment in digital assets.

ALT5 Sigma Corporation Fundamentals Summary

How do ALT5 Sigma's earnings and revenue compare to its market cap?
ALTS fundamental statistics
Market capUS$54.03m
Earnings (TTM)-US$18.65m
Revenue (TTM)US$7.11m

7.6x

P/S Ratio

-2.9x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ALTS income statement (TTM)
RevenueUS$7.11m
Cost of RevenueUS$3.65m
Gross ProfitUS$3.46m
Other ExpensesUS$22.11m
Earnings-US$18.65m

Last Reported Earnings

Sep 28, 2024

Next Earnings Date

n/a

Earnings per share (EPS)-1.33
Gross Margin48.65%
Net Profit Margin-262.26%
Debt/Equity Ratio46.4%

How did ALTS perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2024/12/22 02:30
End of Day Share Price 2024/12/20 00:00
Earnings2024/09/28
Annual Earnings2023/12/30

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .

Analyst Sources

ALT5 Sigma Corporation is covered by 1 analysts. 0 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Ryan McGaverCapstone Investments